Report cover image

Global Rotavirus Infections Drug Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 181 Pages
SKU # APRC20552662

Description

Summary

According to APO Research, The global Rotavirus Infections Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Rotavirus Infections Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Rotavirus Infections Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Rotavirus Infections Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Rotavirus Infections Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Rotavirus Infections Drug include Wuhan Institute of Biological Products Co Ltd, Beijing Minhai Biotechnology Co Ltd, UMN Pharma Inc, Serum Institute of India Ltd, Nanotherapeutics Inc, Medicago Inc, Curevac AG, Biological E Ltd and Bharat Biotech International Ltd, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Rotavirus Infections Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Rotavirus Infections Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Rotavirus Infections Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Rotavirus Infections Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Rotavirus Infections Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Rotavirus Infections Drug sales, projected growth trends, production technology, application and end-user industry.

Rotavirus Infections Drug Segment by Company

Wuhan Institute of Biological Products Co Ltd
Beijing Minhai Biotechnology Co Ltd
UMN Pharma Inc
Serum Institute of India Ltd
Nanotherapeutics Inc
Medicago Inc
Curevac AG
Biological E Ltd
Bharat Biotech International Ltd
Rotavirus Infections Drug Segment by Type

UMN-2001
RV-625
RV-3BB
Rotavac-5C
Others
Rotavirus Infections Drug Segment by Application

Clinic
Hospital
Others
Rotavirus Infections Drug Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rotavirus Infections Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rotavirus Infections Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rotavirus Infections Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Rotavirus Infections Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Rotavirus Infections Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Rotavirus Infections Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Rotavirus Infections Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

181 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Rotavirus Infections Drug Market Size, 2020 VS 2024 VS 2031
1.3 Global Rotavirus Infections Drug Market Size Estimates and Forecasts (2020-2031)
1.4 Global Rotavirus Infections Drug Sales Estimates and Forecasts (2020-2031)
1.5 Global Rotavirus Infections Drug Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Rotavirus Infections Drug Market Dynamics
2.1 Rotavirus Infections Drug Industry Trends
2.2 Rotavirus Infections Drug Industry Drivers
2.3 Rotavirus Infections Drug Industry Opportunities and Challenges
2.4 Rotavirus Infections Drug Industry Restraints
3 Rotavirus Infections Drug Market by Manufacturers
3.1 Global Rotavirus Infections Drug Revenue by Manufacturers (2020-2025)
3.2 Global Rotavirus Infections Drug Sales by Manufacturers (2020-2025)
3.3 Global Rotavirus Infections Drug Average Sales Price by Manufacturers (2020-2025)
3.4 Global Rotavirus Infections Drug Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Rotavirus Infections Drug Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Rotavirus Infections Drug Manufacturers, Product Type & Application
3.7 Global Rotavirus Infections Drug Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Rotavirus Infections Drug Market CR5 and HHI
3.8.2 Global Top 5 and 10 Rotavirus Infections Drug Players Market Share by Revenue in 2024
3.8.3 2024 Rotavirus Infections Drug Tier 1, Tier 2, and Tier 3
4 Rotavirus Infections Drug Market by Type
4.1 Rotavirus Infections Drug Type Introduction
4.1.1 UMN-2001
4.1.2 RV-625
4.1.3 RV-3BB
4.1.4 Rotavac-5C
4.1.5 Others
4.2 Global Rotavirus Infections Drug Sales by Type
4.2.1 Global Rotavirus Infections Drug Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Rotavirus Infections Drug Sales by Type (2020-2031)
4.2.3 Global Rotavirus Infections Drug Sales Market Share by Type (2020-2031)
4.3 Global Rotavirus Infections Drug Revenue by Type
4.3.1 Global Rotavirus Infections Drug Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Rotavirus Infections Drug Revenue by Type (2020-2031)
4.3.3 Global Rotavirus Infections Drug Revenue Market Share by Type (2020-2031)
5 Rotavirus Infections Drug Market by Application
5.1 Rotavirus Infections Drug Application Introduction
5.1.1 Clinic
5.1.2 Hospital
5.1.3 Others
5.2 Global Rotavirus Infections Drug Sales by Application
5.2.1 Global Rotavirus Infections Drug Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Rotavirus Infections Drug Sales by Application (2020-2031)
5.2.3 Global Rotavirus Infections Drug Sales Market Share by Application (2020-2031)
5.3 Global Rotavirus Infections Drug Revenue by Application
5.3.1 Global Rotavirus Infections Drug Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Rotavirus Infections Drug Revenue by Application (2020-2031)
5.3.3 Global Rotavirus Infections Drug Revenue Market Share by Application (2020-2031)
6 Global Rotavirus Infections Drug Sales by Region
6.1 Global Rotavirus Infections Drug Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Rotavirus Infections Drug Sales by Region (2020-2031)
6.2.1 Global Rotavirus Infections Drug Sales by Region (2020-2025)
6.2.2 Global Rotavirus Infections Drug Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Rotavirus Infections Drug Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Rotavirus Infections Drug Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Rotavirus Infections Drug Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Rotavirus Infections Drug Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Rotavirus Infections Drug Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Rotavirus Infections Drug Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Rotavirus Infections Drug Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Rotavirus Infections Drug Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Rotavirus Infections Drug Revenue by Region
7.1 Global Rotavirus Infections Drug Revenue by Region
7.1.1 Global Rotavirus Infections Drug Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Rotavirus Infections Drug Revenue by Region (2020-2025)
7.1.3 Global Rotavirus Infections Drug Revenue by Region (2026-2031)
7.1.4 Global Rotavirus Infections Drug Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Rotavirus Infections Drug Revenue (2020-2031)
7.2.2 North America Rotavirus Infections Drug Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Rotavirus Infections Drug Revenue (2020-2031)
7.3.2 Europe Rotavirus Infections Drug Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Rotavirus Infections Drug Revenue (2020-2031)
7.4.2 Asia-Pacific Rotavirus Infections Drug Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Rotavirus Infections Drug Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Rotavirus Infections Drug Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Wuhan Institute of Biological Products Co Ltd
8.1.1 Wuhan Institute of Biological Products Co Ltd Comapny Information
8.1.2 Wuhan Institute of Biological Products Co Ltd Business Overview
8.1.3 Wuhan Institute of Biological Products Co Ltd Rotavirus Infections Drug Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Wuhan Institute of Biological Products Co Ltd Rotavirus Infections Drug Product Portfolio
8.1.5 Wuhan Institute of Biological Products Co Ltd Recent Developments
8.2 Beijing Minhai Biotechnology Co Ltd
8.2.1 Beijing Minhai Biotechnology Co Ltd Comapny Information
8.2.2 Beijing Minhai Biotechnology Co Ltd Business Overview
8.2.3 Beijing Minhai Biotechnology Co Ltd Rotavirus Infections Drug Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Beijing Minhai Biotechnology Co Ltd Rotavirus Infections Drug Product Portfolio
8.2.5 Beijing Minhai Biotechnology Co Ltd Recent Developments
8.3 UMN Pharma Inc
8.3.1 UMN Pharma Inc Comapny Information
8.3.2 UMN Pharma Inc Business Overview
8.3.3 UMN Pharma Inc Rotavirus Infections Drug Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 UMN Pharma Inc Rotavirus Infections Drug Product Portfolio
8.3.5 UMN Pharma Inc Recent Developments
8.4 Serum Institute of India Ltd
8.4.1 Serum Institute of India Ltd Comapny Information
8.4.2 Serum Institute of India Ltd Business Overview
8.4.3 Serum Institute of India Ltd Rotavirus Infections Drug Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Serum Institute of India Ltd Rotavirus Infections Drug Product Portfolio
8.4.5 Serum Institute of India Ltd Recent Developments
8.5 Nanotherapeutics Inc
8.5.1 Nanotherapeutics Inc Comapny Information
8.5.2 Nanotherapeutics Inc Business Overview
8.5.3 Nanotherapeutics Inc Rotavirus Infections Drug Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Nanotherapeutics Inc Rotavirus Infections Drug Product Portfolio
8.5.5 Nanotherapeutics Inc Recent Developments
8.6 Medicago Inc
8.6.1 Medicago Inc Comapny Information
8.6.2 Medicago Inc Business Overview
8.6.3 Medicago Inc Rotavirus Infections Drug Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Medicago Inc Rotavirus Infections Drug Product Portfolio
8.6.5 Medicago Inc Recent Developments
8.7 Curevac AG
8.7.1 Curevac AG Comapny Information
8.7.2 Curevac AG Business Overview
8.7.3 Curevac AG Rotavirus Infections Drug Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Curevac AG Rotavirus Infections Drug Product Portfolio
8.7.5 Curevac AG Recent Developments
8.8 Biological E Ltd
8.8.1 Biological E Ltd Comapny Information
8.8.2 Biological E Ltd Business Overview
8.8.3 Biological E Ltd Rotavirus Infections Drug Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Biological E Ltd Rotavirus Infections Drug Product Portfolio
8.8.5 Biological E Ltd Recent Developments
8.9 Bharat Biotech International Ltd
8.9.1 Bharat Biotech International Ltd Comapny Information
8.9.2 Bharat Biotech International Ltd Business Overview
8.9.3 Bharat Biotech International Ltd Rotavirus Infections Drug Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Bharat Biotech International Ltd Rotavirus Infections Drug Product Portfolio
8.9.5 Bharat Biotech International Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Rotavirus Infections Drug Value Chain Analysis
9.1.1 Rotavirus Infections Drug Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Rotavirus Infections Drug Production Mode & Process
9.2 Rotavirus Infections Drug Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Rotavirus Infections Drug Distributors
9.2.3 Rotavirus Infections Drug Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.